'''Perzinfotel''' ('''EAA-090''') is a drug which acts as a potent [[NMDA antagonist]].<ref>{{cite journal | pmid = 9457246 | doi=10.1021/jm970504g | volume=41 | title=Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere | date=January 1998 | journal=J. Med. Chem. | pages=236–46 | last1 = Kinney | first1 = WA | last2 = Abou-Gharbia | first2 = M | last3 = Garrison | first3 = DT | display-authors = 3 | last4 = et al}}</ref> It has [[neuroprotective]] effects and has been investigated for the treatment of [[stroke]],<ref>{{cite journal | last1 = Sun | first1 = L | last2 = Chiu | first2 = D | last3 = Kowal | first3 = D | last4 = Simon | first4 = R | last5 = Smeyne | first5 = M | last6 = Zukin | first6 = RS | last7 = Olney | first7 = J | last8 = Baudy | first8 = R | last9 = Lin | first9 = S | date = Aug 2004 | title = Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride) | url = | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 310 | issue = 2| pages = 563–70 | doi = 10.1124/jpet.104.066092 | pmid = 15075380 }}</ref> but lacks [[analgesic]] effects.<ref>{{cite journal | pmid = 15764736 | doi=10.1124/jpet.105.084467 | volume=313 | title=Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity | date=June 2005 | journal=J. Pharmacol. Exp. Ther. | pages=1379–86 | last1 = Brandt | first1 = MR | last2 = Cummons | first2 = TA | last3 = Potestio | first3 = L | last4 = Sukoff | first4 = SJ | last5 = Rosenzweig-Lipson | first5 = S}}</ref> Nevertheless, it shows a good safety profile compared to older drugs, although further development of this drug has been discontinued.<ref>http://adisinsight.springer.com/drugs/800009946</ref>
